INVIRASE

This brand name is authorized in United States. It is also authorized in Australia, Austria, Cyprus, Estonia, Hong Kong SAR China, Ireland, Lithuania, Netherlands, Poland.

Active ingredients

The drug INVIRASE contains one active pharmaceutical ingredient (API):

1	Saquinavir UNII UHB9Z3841A - SAQUINAVIR MESYLATE
	Saquinavir selectively inhibits the HIV protease, thereby preventing the creation of mature infectious virus particles. The HIV protease is an essential viral enzyme required for the specific cleavage of viral gag and gag-pol polyproteins.
	Read more about Saquinavir

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
INVIRASE Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
J05AE01	Saquinavir	J Antiinfectives for systemic use → J05 Antivirals for systemic use → J05A Direct acting antivirals → J05AE Protease inhibitors
Discover more medicines within J05AE01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	10335Y
EE	Ravimiamet	1199516, 1199527
HK	Department of Health Drug Office	42535, 54309
LT	Valstybinė vaistų kontrolės tarnyba	1010803, 1028765
NL	Z-Index G-Standaard, PRK	78603
PL	Rejestru Produktów Leczniczych	100138155, 100311100
US	FDA, National Drug Code	0004-0244